{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Heldman MR"],"funding":["National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","NHLBI NIH HHS","National Heart, Lung, and Blood Institute"],"pagination":["e13933"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9780159"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(6)"],"pubmed_abstract":["<h4>Background</h4>Epstein-Barr virus (EBV) seronegative solid organ transplant recipients (SOTRs) are at increased risk for post-transplant lymphoproliferative disorder (PTLD). Assays for EBV serostatus assess antibody to both EBV viral capsid antigen (VCA) and Epstein-Barr nuclear antigen-1 (EBNA-1), but PTLD risk among SOT recipients with discordant VCA and EBNA-1 results is unknown.<h4>Methods</h4>We performed a retrospective, single-center cohort study to determine the risk of PTLD among adult (≥ 18 years) SOTRs with discordant pre-transplant VCA and EBNA-1 IgG compared to that of SOTRs with concordantly negative or concordantly positive serology using univariable and multivariable Cox-proportional hazards models.<h4>Results</h4>Of 4106 SOTRs, the number (%) who were concordantly posi"],"journal":["Transplant infectious disease : an official journal of the Transplantation Society"],"pubmed_title":["Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients."],"pmcid":["PMC9780159"],"funding_grant_id":["K23 HL143050","T32 AI118690","T32AI118690","HL143050"],"pubmed_authors":["Limaye AP","Fisher CE","Pepper G","Rakita RM","Edlefsen KL","Kapnadak SG","Heldman MR"],"additional_accession":[]},"is_claimable":false,"name":"Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.","description":"<h4>Background</h4>Epstein-Barr virus (EBV) seronegative solid organ transplant recipients (SOTRs) are at increased risk for post-transplant lymphoproliferative disorder (PTLD). Assays for EBV serostatus assess antibody to both EBV viral capsid antigen (VCA) and Epstein-Barr nuclear antigen-1 (EBNA-1), but PTLD risk among SOT recipients with discordant VCA and EBNA-1 results is unknown.<h4>Methods</h4>We performed a retrospective, single-center cohort study to determine the risk of PTLD among adult (≥ 18 years) SOTRs with discordant pre-transplant VCA and EBNA-1 IgG compared to that of SOTRs with concordantly negative or concordantly positive serology using univariable and multivariable Cox-proportional hazards models.<h4>Results</h4>Of 4106 SOTRs, the number (%) who were concordantly posi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-21T23:07:19.584Z","creation":"2025-04-05T19:04:16.285Z"},"accession":"S-EPMC9780159","cross_references":{"pubmed":["36000190"],"doi":["10.1111/tid.13933"]}}